The park integrates a full industrial chain of services in biopharmaceuticals, including CRO, CDMO, CSO, and EHS. It is dedicated to technology incubation in the healthcare sector and holds the distinction of being the first park in China to implement the Marketing Authorization Holder (MAH) system. Through pioneering reforms, it has established a comprehensive third-party platform for innovative technology transfer (CRO+CDMO+CSO) that specifically addresses the challenges in the R&D-to-market process for medical devices. This platform assists resident companies in obtaining regulatory approvals efficiently and compliantly, fostering their healthy and rapid development.

Suzhou BASECARE Medical holds the distinction of being the first company in China to successfully obtain cross-provincial product registration under the Marketing Authorization Holder (MAH) system. In 2020, the company secured the Class III Medical Device Registration Certificate for its Preimplantation Genetic Screening (PGS) product. This landmark certification directly facilitated its successful listing on the Main Board of the Hong Kong Stock Exchange in 2021, establishing the company as China's first publicly-traded entity in the Next-Generation Sequencing (NGS) sector for the assisted reproductive field.

Darui Biotechnology obtained the Class III medical device registration certificate for its NIPT products and supporting gene sequencing instruments in 2014. In 2015, the company became the first listed enterprise in China’s second-generation sequencing (NGS) sector. During this period, the company’s valuation increased from RMB 120 million to RMB 2.4 billion.